OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017
03 August 2017 - 10:00PM
OPKO Health, Inc. (NASDAQ:OPK), a multinational
biopharmaceutical and diagnostics company, will announce operating
and financial results for the three months and six months ended
June 30, 2017, after the close of the U.S. financial markets on
Tuesday, August 8, 2017.
OPKO’s senior management will provide a business update and
discuss its financial results in a conference call and live audio
webcast beginning at 4:30 p.m. Eastern time on Tuesday, August 8,
2017.
Conference Call & Webcast Information
WHEN: Tuesday, August 8, 2017, 4:30 p.m. Eastern time.DOMESTIC
DIAL-IN: (866)
634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454 PASSCODE: 65755948WEBCAST:
http://investor.opko.com/events.cfm
For those unable to participate in the live conference call or
webcast, a replay will be available beginning August 8, 2017 two
hours after the close of the conference call. To access the replay,
dial (855) 859-2056 or (404) 537-3406. The replay passcode is:
65755948. The replay can be accessed for a period of time on OPKO’s
website at http://investor.opko.com/events.cfm.
About OPKO Health, Inc.OPKO Health is a
diversified healthcare company that seeks to establish
industry-leading positions in large, rapidly growing markets. Our
diagnostics business includes Bio-Reference Laboratories, the
nation’s third-largest clinical laboratory with a core genetic
testing business and a 400-person sales and marketing team to drive
growth and leverage new products, including the 4Kscore® prostate
cancer test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (launched in November 2016), VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched
by partner TESARO and IV formulation pending FDA approval),
OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes
and obesity which is a clinically advanced drug candidate among the
new class of GLP-1 glucagon receptor dual agonists, and OPK88004,
an androgen receptor modulator for androgen deficiency indications.
Our biologics business includes hGH-CTP, a once weekly human growth
hormone injection (in phase 3 and partnered with Pfizer), and a
long acting Factor VIIa drug for hemophilia in Phase 2a. More
information available at www.opko.com.
Contacts:
OPKO Health, Inc.David Malina, 305-575-4137Investor
Relationsdmalina@opko.com
Or
InvestorsLHAAnne Marie Fields, 212-838-3777afields@lhai.com
OrBruce Voss, 310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024